



Aquavit Pharmaceuticals AG Acquires Axon Technologies, Expanding Global AI and Life-Science Capabilities

Aquavit Pharmaceuticals acquires Axon Technologies, uniting life-science innovation and AI to strengthen global leadership.

ZUG, SWITZERLAND, September 24, 2025 /EINPresswire.com/ -- Aquavit Pharmaceuticals AG today announced the successful acquisition and integration of Axon Technologies AG, formerly known as Genève Technologies, marking a strategic leap forward in artificial intelligence (AI) and advanced life-science innovation.

This milestone was formally certified by the Kaiser Odermatt & Partners, official Notary of the Canton of Zug on 23 September 2025, completing the extraordinary shareholders' resolutions that approved the surviving name to Aquavit Pharmaceuticals AG, adopted new Articles of Association, and confirmed Sobin Chang as Chairman of the Board of Directors.

"By bringing Axon Technologies into the Aquavit family, we fuse world-class expertise in pharmaceutical development with state-of-the-art artificial intelligence," said Sobin Chang, MPH, CEO and Chairman. "This combination positions us to accelerate drug and device developments, optimize global medical logistics and commercialization, and pioneer AI-driven healthcare solutions."

Aquavit Pharmaceuticals AG also retains the flexibility to acquire complementary businesses and to manage intellectual property and related assets worldwide.

Strengthening AI Leadership

Axon Technologies—formerly incorporated as Genève Technologies—is recognized for its purpose of "developing and commercializing applications and technologies in the field of artificial intelligence." Now as part of Aquavit Pharmaceuticals AG, the company will integrate this AI focus across:

- Predictive modeling and drug-discovery pipelines
- State-of-the-art device and microchannel technologies
- AI powered PITO (Personalized Injection Treatment Optimizer)
- Advanced clinical-trial data analysis

Intelligent automation of regulatory and compliance processes
First AI powered global commercial platform in healthcare
Smart management of Intellectual property assets
Innovative financing solutions

Global Vision

Aquavit Pharmaceuticals AG is positioned to scale internationally, leveraging Switzerland's innovation ecosystem while serving partners and patients worldwide.

About Aquavit Pharmaceuticals AG

Aquavit Pharmaceuticals AG is a Swiss-based life-science and technology company dedicated to breakthrough therapies, advanced drug-delivery platforms, and AI-driven healthcare solutions. By uniting cutting-edge pharmaceutical expertise with next-generation artificial intelligence, Aquavit aims to redefine patient outcomes and global medical logistics.

Jessica Quiles

Aquavit Group of Companies

+1 212-253-0523

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/852056158>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.